• Wondering if PACS Group at US$30.59 is still priced for opportunity or already reflects the story? This breakdown will help you frame what the current share price might be implying.
• The stock has had a mixed run, with a 1 year return of 180.4% contrasted by a 7 day return of an 8.5% decline, a 30 day return of a 22.2% decline, and a year to date return of a 22.6% decline, which can change how the market views its risk and reward trade off.
• Recent coverage of PACS Group has focused on its presence in the US healthcare space and how investors are reacting to its relatively short trading history as a listed stock. This backdrop helps explain why the share price has moved sharply over shorter periods while still showing a strong 1 year return.
• PACS Group currently has a value score of 1/6. The next sections will look at how different valuation approaches line up, before finishing with a way to think about value that goes beyond any single model.

PACS Group scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: PACS Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return to arrive at an estimated intrinsic value per share.

For PACS Group, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is reported at $312.06 million. Looking ahead, one analyst estimate points to free cash flow of $116 million in 2027, with additional annual figures out to 2035 extrapolated by Simply Wall St rather than based on direct analyst coverage.

Putting all those projected cash flows together and discounting them back to today gives an estimated intrinsic value of $8.27 per share. Compared with the recent share price of $30.59, this DCF output suggests PACS Group is very expensive, with an implied overvaluation of about 270.1%.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests PACS Group may be overvalued by 270.1%. Discover 61 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for PACS Group.

Approach 2: PACS Group Price vs Earnings

For profitable companies, the P/E ratio is a familiar way to think about value because it links what you pay for each share to the earnings that company is currently generating. It gives you a quick sense of how many dollars investors are willing to pay for one dollar of earnings.

What counts as a “normal” or “fair” P/E will usually depend on how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth expectations or higher risk can point to a lower multiple.

PACS Group is trading on a P/E of 25.10x, compared with the Healthcare industry average of 20.85x and a peer average of 22.04x. Simply Wall St’s Fair Ratio for PACS Group is 20.63x, which is its proprietary view of what a reasonable P/E might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This Fair Ratio can be more tailored than a simple comparison with peers or the broad industry because it adjusts for those company level characteristics. On this basis, PACS Group’s current P/E is higher than the Fair Ratio, which indicates that the shares may be expensive on an earnings basis.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your PACS Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you can build on Simply Wall St’s Community page that link your view of PACS Group’s business, your forecasts for revenue, earnings and margins, and your fair value estimate. You can then compare that fair value to the current price to help you judge whether the stock looks attractive or not. Each Narrative updates as new news or earnings arrive, and different investors may anchor on the more bullish US$40 analyst target or the more cautious US$32 target depending on how they interpret the same information.

Do you think there's more to the story for PACS Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.